FDA accepts Synergy's marketing application for expanded use of Trulance; shares ahead 4% premarket Jun. 7, 2017 9:18 AM • SA Editor Douglas W. House
The FDA accepts for review Synergy Pharmaceuticals' (NASDAQ:SGYP) supplemental New Drug Application (sNDA) seeking approval of TRULANCE (plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C). The agency's action date (PDUFA) is January 24, 2018. The FDA approved TRULANCE to treat chronic idiopathic constipation in January. Share are up 4% premarket on increased volume.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.